ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 83 filers reported holding ORIC PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $155,745 | -8.5% | 25,743 | +17.4% | 0.00% | – |
| Q2 2023 | $170,216 | +18.7% | 21,935 | -12.8% | 0.00% | – |
| Q1 2023 | $143,452 | -3.2% | 25,167 | 0.0% | 0.00% | – |
| Q4 2022 | $148,234 | +83.0% | 25,167 | 0.0% | 0.00% | – |
| Q3 2022 | $81,000 | -48.7% | 25,167 | -28.6% | 0.00% | – |
| Q2 2022 | $158,000 | +69.9% | 35,270 | +102.9% | 0.00% | – |
| Q1 2022 | $93,000 | -67.4% | 17,384 | -10.5% | 0.00% | – |
| Q4 2021 | $285,000 | -37.8% | 19,422 | -11.3% | 0.00% | – |
| Q3 2021 | $458,000 | +27.9% | 21,904 | +8.4% | 0.00% | – |
| Q2 2021 | $358,000 | -12.3% | 20,212 | +21.2% | 0.00% | – |
| Q1 2021 | $408,000 | -27.1% | 16,683 | +0.8% | 0.00% | – |
| Q4 2020 | $560,000 | +359.0% | 16,546 | +240.0% | 0.00% | – |
| Q3 2020 | $122,000 | -18.7% | 4,867 | +9.5% | 0.00% | – |
| Q2 2020 | $150,000 | – | 4,445 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 4,768,181 | $99,703,000 | 11.34% |
| Euclidean Capital LLC | 777,193 | $16,251,000 | 7.90% |
| Memorial Sloan Kettering Cancer Center | 602,272 | $12,594,000 | 7.85% |
| Invus Financial Advisors, LLC | 1,007,575 | $21,068,000 | 5.64% |
| EcoR1 Capital, LLC | 3,468,944 | $72,536,000 | 2.52% |
| EMERALD ADVISERS, LLC | 726,236 | $15,186,000 | 0.55% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 742,666 | $15,529,000 | 0.54% |
| Orbimed Advisors | 2,337,574 | $48,879,000 | 0.54% |
| Casdin Capital, LLC | 601,515 | $12,578,000 | 0.31% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 53,000 | $1,104,000 | 0.27% |